top of page
png_edited.png

Covid-19 Vaccine

  • parminder8
  • Aug 23, 2021
  • 1 min read

The Food and Drug Administration’s decision Monday to grant full approval to Pfizer-BioNTech's two-dose Covid-19 vaccine pushed markets higher, boosting the Dow Jones Industrial Average by 300 points and propelling the S&P 500 and the Nasdaq to new highs. Investors appeared to express confidence that the move could be an inflection point for the economic recovery.


SOURCE: NBC NEWS



 
 
 

Comments


CONTACT US

Main Office

252 Ponce de León Ave.

City Towers Suite 1403
San Juan, PR 00918

EMAIL

info@lyonbern.com

PHONE

787-395-7325

  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube

Disclosure:  Lyon Bern, LLC is a Registered Investment Adviser and is in the business of consulting and advising its clients in wealth and asset management. Each client's diversification between Lyon Bern's portfolios will be made individually and based on the client's Investment Policy Statement. Please remember that past performance may not be indicative of future results. Different types of investments involve varying degrees of risk, and there can be no assurance that the future performance of any specific investment, investment strategy, or product referred to directly or indirectly in this document will be profitable, equal any corresponding indicated historical performance level(s), or be suitable for your portfolio. Due to various factors, including changing market conditions, the content may no longer be reflective of current opinions or positions. Moreover, you should not assume that any discussion or information contained in this document serves as the receipt of, or as a substitute for, personalized investment advice from Lyon Bern, LLC. To the extent that a reader has any questions regarding the applicability of any specific issue discussed above to his/her individual situation, he/she is encouraged to consult with the professional investment advisor. A copy of our current written investment advisory agreement discussing our advisory services and fees is available for review upon request.

bottom of page